Comprehensive medication guide to RhoGAM including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay when billed under the medical benefit for in-office administration; covered for standard obstetric indications without prior authorization on most commercial plans. Pharmacy benefit copays vary by plan tier.
Estimated Cash Pricing
$130–$250 per full dose (300 mcg) at retail pharmacies without insurance; as low as $122–$139 with a GoodRx coupon. Two doses are typically needed during pregnancy, bringing the total to $260–$500.
Medfinder Findability Score
30/100
Summarize with AI
On this page
RhoGAM is the brand name for Rho(D) immune globulin (human), a sterile biological medication made from human blood plasma. It contains concentrated IgG antibodies against the Rh(D) antigen — a protein found on red blood cells in most people. RhoGAM was first FDA-approved in 1968 and is manufactured by Kedrion Biopharma Inc.
RhoGAM is most commonly given to Rh-negative pregnant patients to prevent Rh isoimmunization — a process by which the mother's immune system could otherwise develop lasting antibodies against Rh-positive blood cells, potentially endangering future pregnancies. It is given as an intramuscular (IM) injection at 26–28 weeks gestation and within 72 hours of delivery.
It is also used after miscarriage, ectopic pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma, or any event that may cause fetal Rh-positive blood cells to enter the mother's circulation. RhoGAM is also indicated for prevention of Rh immunization after transfusion of Rh-incompatible blood products.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
RhoGAM works through a principle called passive antibody immunosuppression. It contains pre-made anti-D antibodies sourced from immunized Rh-negative plasma donors. When injected into an Rh-negative patient, these antibodies immediately bind to any Rh-positive fetal red blood cells in the mother's bloodstream.
Once coated by the RhoGAM antibodies, the Rh-positive cells are cleared from the circulation before the mother's own immune system can "learn" to make its own lasting anti-D antibodies. This prevents sensitization — the development of immune memory — which could otherwise attack future Rh-positive babies.
The protection from a single dose lasts approximately 12 weeks, after which the passively transferred antibodies are metabolized. RhoGAM does not create permanent immunity — each pregnancy or sensitizing event requires a new dose. Clinical studies show the two-dose schedule (28 weeks + postpartum) reduces the Rh sensitization rate from about 15% to approximately 0.1–0.2%.
300 mcg (1500 IU) — Prefilled syringe for IM injection
Full dose — for pregnancies at or beyond 13 weeks, postpartum, and transfusion exposure
50 mcg (250 IU) — Prefilled syringe for IM injection (MICRhoGAM)
Mini dose — for pregnancy loss or invasive procedures at 12 weeks gestation or less
RhoGAM is currently in active shortage and has been since December 2023. The shortage stems from a supply constraint in the anti-D plasma market — the human-derived raw material from which RhIG is manufactured — combined with manufacturing issues at Kedrion Biopharma. With only four FDA-licensed manufacturers of Rho(D) immune globulin in the United States, any disruption in one creates significant ripple effects.
Retail pharmacies have experienced the most severe stocking gaps. Hospitals, OB clinics, and infusion centers often have better access through institutional supply channels. Three alternative products — HyperRHO S/D (Grifols), Rhophylac (CSL Behring), and WinRho SDF (Kamada) — are clinically interchangeable for obstetric use and have been more available during the shortage.
To find RhoGAM or an equivalent in stock near you, medfinder contacts pharmacies in your area and texts you which ones can fill your prescription — no phone calls required.
RhoGAM is not a controlled substance, so no special DEA licensing is required to prescribe it. Any licensed prescriber with appropriate clinical scope can order it. It must be administered by a healthcare professional — patients cannot self-inject.
Obstetricians and Gynecologists (OB/GYNs)
Certified Nurse Midwives (CNMs)
Family Medicine Physicians
Emergency Medicine Physicians
Hematologists (for ITP indication)
Nurse Practitioners (NPs) and Physician Assistants (PAs) — scope varies by state
Telehealth providers can assess eligibility and write the prescription, but the injection must be administered in-person at a clinic, hospital, or pharmacy with injection services. Maven Clinic and similar obstetric telehealth platforms can connect Rh-negative patients with virtual OB/GYN consultants who can prescribe RhIG.
No. RhoGAM (Rho(D) immune globulin) is not a controlled substance and has no DEA scheduling. Any licensed prescriber — including OB/GYNs, certified nurse midwives, family medicine physicians, nurse practitioners, and physician assistants — can prescribe it without any special DEA registration or controlled substance requirements.
Because it is a biologic made from human plasma, RhoGAM does require a prescription — it cannot be purchased over the counter. It must also be administered by a healthcare professional as an intramuscular injection. Prescriptions cannot be filled via mail-order for self-injection; clinical administration is required.
Most patients tolerate RhoGAM well. Common side effects include:
Injection site reactions: pain, swelling, redness, warmth
Low-grade fever (below 101°F)
Headache
Chills
Fatigue or general malaise
Anaphylaxis: Hives, difficulty breathing, throat swelling, severe dizziness — call 911
Hemolysis (IV formulation): Fever with back pain, red/dark urine, unusual weakness, shortness of breath
Blood clot signs: Sudden numbness, slurred speech, chest pain, leg swelling/warmth
Know what you need? Skip the search.
HyperRHO S/D (Grifols)
Same active ingredient, available in full dose (300 mcg) and mini dose (50 mcg). IM only. Generally more available than RhoGAM during the current shortage.
Rhophylac (CSL Behring)
300 mcg IM or IV. Uses ChromaPlus manufacturing process. Approved for obstetric prophylaxis and transfusion exposure. Generally available.
WinRho SDF (Kamada)
300 mcg IM or IV. IV formulation approved for ITP in Rh-positive patients. Shortage resolved August 2024. Some large vial sizes discontinued.
Prefer RhoGAM? We can find it.
Live virus vaccines (MMR, varicella/Varivax)
moderateRhoGAM can reduce the effectiveness of live attenuated vaccines. Delay live vaccines at least 12 weeks after RhoGAM. Non-live vaccines (flu, COVID, Tdap) are not affected.
CAR-T cell therapies (axicabtagene, tisagenlecleucel, others)
majorConcurrent use increases immunosuppressive effects and risk of infection. Avoid or use alternative. Primarily relevant to oncology/ITP patients, not routine obstetric use.
Efgartigimod alfa (Vyvgart)
moderateMay reduce RhoGAM effectiveness by blocking neonatal Fc receptor (FcRn). Monitor closely for reduced protection if these medications must be used together.
RhoGAM is one of the most impactful preventive medications in obstetric medicine. Since its introduction in 1968, it has nearly eliminated Rh hemolytic disease of the newborn in countries with universal prophylaxis programs. For Rh-negative pregnant patients, getting the shot at 28 weeks and postpartum is one of the most important steps in a healthy pregnancy.
The ongoing shortage since 2023 has made access more challenging — but not impossible. HyperRHO S/D, Rhophylac, and WinRho SDF are all clinically equivalent alternatives. Hospitals and OB clinics often have stock when retail pharmacies do not. Writing brand-flexible prescriptions helps maximize what's available in your area.
If you're struggling to find RhoGAM in stock, medfinder calls pharmacies near you to locate which ones have your medication available — so you can focus on your pregnancy instead of the phone.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini